Product
NEO100
2 clinical trials
12 indications
Indication
ResidualIndication
Pediatric Tumor of CNSIndication
Pediatric Brain TumorIndication
Diffuse Midline GliomaIndication
H3 K27M-MutantIndication
Pediatric Brain Stem TumorIndication
PineocytomaIndication
Choroid Plexus CarcinomaIndication
ChildhoodIndication
Spinal Cord TumorIndication
High-Grade GliomaClinical trial
An Open-Label, Phase 2 Study of NEO100 in Participants With Residual, Progressive or Recurrent High-Grade MeningiomaStatus: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
An Open Label, Phase 1b Safety, Dose-finding, Brain Tumor Delivery, and Pharmacokinetics Study of Intranasal NEO100 in Patients With Pediatric-type Select Brain TumorsStatus: Not yet recruiting, Estimated PCD: 2024-10-31